DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Marie Hartley, Staff Writer, 2009.
Amoebiasis is a disease caused by Entamoeba histolytica, a protozoa which is found worldwide. Humans are the natural reservoir of E. histolytica, and infection occurs via faecal-oral transmission (e.g. contaminated hands, water, or food, and oral-anal sex). The main symptom of infection is diarrhoea.
There is a higher incidence of amoebiasis in developing countries where barriers between human faeces and food and water supplies are inadequate. Risk factors for amoebiasis in developed countries include travellers to endemic regions, men who have sex with men, and immunosuppressed or institutionalised people.
The life cycle of E. histolytica includes the formation of cysts and trophozoites, both of which are passed in faeces. Cysts can survive days to weeks in the external environment and are mainly responsible for transmission of disease.
Annually an estimated 50 million people are infected by invasive E. histolytica, leading to 100,000 deaths.
Many cases of amoebiasis are asymptomatic with the cysts and trophozoites remaining confined to the intestinal lumen (inside the tube of the intestine). However in some patients the trophozoites invade the intestinal mucosal wall leading to bloody diarrhoea and colitis. The trophozoites can also invade the bloodstream and spread the infection to other organs including the liver (most common), lung, heart, brain, and skin.
Cutaneous amoebiasis is very rare, but is easily diagnosed and treated. E. histolytica can spread to the skin and mucous membranes either by:
|Clinical form||Clinical features|
|Amoebic liver abscess||
The most common method of diagnosis of amoebiasis is microscopic identification of E. histolytica cysts and trophozoites in faeces, liver abscess aspirates, or biopsy samples. Note: E. histolytica cannot be distinguished microscopically from E. dispar, which is harmless. Confirmation of E. histolytica infection requires serology, antigen detection, or identification of E. histolytica genetic material:
Intestinal amoebiasis is treated with a luminal agent, such as iodoquinol, paromomycin, or diloxanide furoate. These agents are not approved by Medsafe for use in New Zealand but may be obtained by medical practitioners through their manufacturers under Section 29.
Following treatment, invasive amoebiasis carries a good prognosis. Fulminant colitis and liver abscess rupture are associated with higher mortality rates.
See the DermNet NZ bookstore.
© 2021 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.